this is actually true i have to agree with tooluck However even at a maximum output of 190m doses pa gsk would still be short of production should govt continue to move toward rebalancing the stockpile - replacing expiring product and dealing with resistance to tamiflu and other contingencies. so regardless of production/sales for the next few quarters these fundamentals are not going to change anytime soon.if anything the long term production of relenza must go up until lani comes online
BTA Price at posting:
$2.22 Sentiment: LT Buy Disclosure: Held
